Since its inception in 1984, the goal of the CSHL FACS Shared Resource has been to give Cancer Center members access to state-of-the-art flow cytometry equipment and support. The Resource has evolved with emerging technologies and changing research needs. In 1984, the primary use was separation of cells by DNA content or by expressed cell-surface antigens. The advent of fluorescent markers (such as the green fluorescent protein GFP) ushered in a new phase in FACS usage, as Cancer Center members used GFP to track transfected cells, and to isolate particular populations of cells from complex mixtures. Increases in the speed and efficiency of sorting by FACS have enabled completion of experiments that once would have been impossible or impractical?such as the isolation of large quantities of tumor or stem cells for genomic and genetic analyses. The recent introduction of the new generation of proteins that fluoresce in various colors and are less toxic than their predecessors, changed the requirements for flow cytometers and increased the demand for the Resource. In response to these demands, the FACS Shared Resource has undergone an extensive series of changes?in location, instrumentation, and personnel?designed to expand FACS capabilities at CSHL, and improve the efficiency and reliability of flow cytometry for Cancer Center members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA045508-25
Application #
8382434
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
25
Fiscal Year
2012
Total Cost
$255,158
Indirect Cost
$135,779
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Cheng, Derek; Tuveson, David (2018) Kras in Organoids. Cold Spring Harb Perspect Med 8:
Albrengues, Jean; Shields, Mario A; Ng, David et al. (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361:
Cook, Natalie; Basu, Bristi; Smith, Donna-Michelle et al. (2018) A phase I trial of the ?-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 118:793-801
Melnikov, Sergey V; Rivera, Keith D; Ostapenko, Denis et al. (2018) Error-prone protein synthesis in parasites with the smallest eukaryotic genome. Proc Natl Acad Sci U S A 115:E6245-E6253
Krishnan, Navasona; Bonham, Christopher A; Rus, Ioana A et al. (2018) Harnessing insulin- and leptin-induced oxidation of PTP1B for therapeutic development. Nat Commun 9:283
Pommier, Arnaud; Anaparthy, Naishitha; Memos, Nicoletta et al. (2018) Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science 360:
Krishnan, Navasona; Felice, Christy; Rivera, Keith et al. (2018) DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease. Genes Dev 32:944-952
Tiriac, Herve; Bucobo, Juan Carlos; Tzimas, Demetrios et al. (2018) Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc 87:1474-1480
Nattestad, Maria; Goodwin, Sara; Ng, Karen et al. (2018) Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNA sequencing of a breast cancer cell line. Genome Res 28:1126-1135
Connell, Claire M; Raby, Sophie E M; Beh, Ian et al. (2018) Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist 23:116-117

Showing the most recent 10 out of 380 publications